Reuters logo
BRIEF-Momenta Pharmaceuticals says positive top-line phase 3 results for M923, a proposed Humira biosimilar
November 29, 2016 / 1:30 PM / a year ago

BRIEF-Momenta Pharmaceuticals says positive top-line phase 3 results for M923, a proposed Humira biosimilar

Nov 29 (Reuters) - Momenta Pharmaceuticals Inc :

* Momenta Pharmaceuticals announces positive top-line phase 3 results for M923, a proposed Humira (adalimumab) biosimilar

* Says M923 in patients with moderate-to-severe chronic plaque psoriasis met its primary endpoint

* Momenta Pharmaceuticals - proportion of subjects in study who achieved primary endpoint following 16 weeks of treatment was equivalent between M923 and Humira

* Equivalence was also achieved in all secondary efficacy endpoints of phase 3 M923 study

* Momenta Pharmaceuticals Inc says positive data support biosimilarity of M923 and further advance co toward its goal of gaining regulatory approval Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below